




February 2010

Volume 15 · Numbers 3/4

pp. 81–160



Cover Story

The featured review by Craig P. Carden, Debashis Sarker, Sophie Postel-Vinay, Timothy A. Yap, Gerthardt Attard, Udai Banerji, Michelle D. Garrett, George V. Thomas, Paul Workman, Stan B. Kaye and Johann S. de Bono in this special issue of Drug Discovery Today focusing on biomarkers highlights that the current slow, costly and inefficient method of developing anti-cancer drugs can be improved by the use of predictive biomarkers to select patients for phase I and II trials. In the article, they suggest a new model for clinical trial design via the recruitment of patients for selective anti-cancer agents by the use of predictive clinical biomarkers. I would like to acknowledge the help given to me by Galina Ananin of Oxford Global in the preparation of this special issue.

REVIEWS

KEYNOTE

88 Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

Craig P. Carden, Debashis Sarker, Sophie Postel-Vinay, Timothy A. Yap, Gerthardt Attard, Udai Banerji, Michelle D. Garrett, George V. Thomas, Paul Workman, Stan B. Kaye and Johann S. de Bono

POST SCREEN

98 Circulating tumour-derived predictive biomarkers in oncology

Darren R. Hodgson, Robert Wellings, Maria C.M. Orr, Rose McCormack, Michael Malone, Ruth E. Board and Mireille V. Cantarini

102 Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies

Roy van der Meel, William M. Gallagher, Sabrina Oliveira, Aisling E. O'Connor, Raymond M. Schiffelers and Annette T. Byrne

115 Progress towards personalized medicine

Stewart Bates

121 From biomarker strategies to biomarker activities and back

Alain J. van Gool, Brian Henry and Erik D. Sprengers

127 Isotopic biomarker discovery and application in translational medicine

Henry K. Bayele, Arturo Chiti, Rodney Colina, Octavio Fernandes, Baldip Khan, Rajagopal Krishnamoorthy, Hilal Özdağ and Rose Ann Padua

137 Use of biomarkers in the discovery of novel anti-schizophrenia drugs

Jens D. Mikkelsen, Morten S. Thomsen, Henrik H. Hansen and Jacek Lichota

142 A guidance for renal biomarker lead optimization and use in translational pharmacodynamics

Josef S. Ozer

148 The quest for biomarkers in tuberculosis

Shreemanta K. Parida and Stefan H.E. Kaufmann

DRUG DISCOVERY TODAY**Editorial****Editor:** Steve Carney**Assistant Editor:** Kirsty Strawbridge**Content Development Manager:** Joanna Aldred**Journal Manager:** Basil Nyaku**Publisher:** Jaap van Harten**Editorial Enquiries:***Drug Discovery Today*

Elsevier

32 Jamestown Road, London, NW1 7BY, UK

Tel: +44 (0)20 7424 4200

Fax: +44 (0)1865 853067

Email: ddt@drugdiscoverytoday.com

ADVISORY EDITORIAL BOARD**Jurgen Bajorath** *University of Bonn, Germany***Walter Blackstock** *Experimental Therapeutics
Centre, Singapore***David Brayden** *University College Dublin, Ireland***Paul Caron** *Vertex Pharmaceuticals, USA***David Cavalla** *Arachnova, UK***David Clark** *Argenta Discovery, UK***Dalia Cohen** *Rosetta Genomics, USA***Donald Daley** *Argenta Discovery, UK***Sean Ekins** *ACT LLC and Collaborations in
Chemistry, USA***Hans-Peter Fischer** *GeneData, Switzerland***Peter Ghazal** *University of Edinburgh, UK***Christopher M. Hill** *Organon, UK***Nick Hird** *Takeda Chemical Industries, Japan***Enoch Huang** *Pfizer, USA***Thomas Joos** *University of Tuebingen, Germany***Vincent H.L. Lee** *Chinese University of Hong Kong,
Hong Kong***David Lewin** *Yale University, USA***Christopher A. Lipinski** *Melior Discovery, USA***Lorenz Mayr** *Novartis, Switzerland***Nick Meanwell** *Bristol-Myers Squibb, USA***BK Muralidhara** *Pfizer Global Biologics, St. Louis,
USA***Mark Murcko** *Vertex Pharmaceuticals, USA***Fajun Nan** *Shanghai Institute of Materia Medica,
China***Pradeep Nathan** *Experimental Medicine, GSK and
University of Cambridge***Gitte Neubauer** *Cellzome, Germany***Eric Neumann** *Teranode, USA***Tim Peakman** *UK Biobank, UK***Norton Peet** *Aurigene, USA***Manuel Peitsch** *Novartis, Switzerland***Kurt Rasmussen** *Eli Lilly and Co. Ltd. USA***Janice Reichert** *Tufts Center for the Study of Drug
Development, USA***John Reidhaar-Olson** *Hoffmann-La Roche, USA***Mike Romanos** *GlaxoSmithKline, UK***Raymond C. Rowe** *Intelligensys, UK***Andreas Russ** *University of Oxford, UK***Esther Schmid** *Pfizer, UK***Jonathan Sheldon** *Inforsense, UK***Michael Snyder** *Yale University, USA***Susie Stephens** *Eli Lilly and Co. Ltd., USA***Robert Strausberg** *The J. Craig Venter Institute, USA***Donny Strosberg** *Scripps Florida, USA***Yuichi Sugiyama** *University of Tokyo, Japan***David Szymkowski** *Xencor, USA***Nick Terrett** *Ensemble Discovery, USA***Vladimir Torchilin** *Northeastern University, Boston,
USA***Mark Whittaker** *Evotec OAI, UK***Hans Winkler** *Johnson and Johnson, Belgium***Limsoon Wong** *Laboratories for Information
Technology (LIT), Singapore***X.F. Steven Zheng** *Robert Wood Johnson Medical
School, USA*

DRUG DISCOVERY TODAY

EDITORIAL

81 Biologics: a new approach needed?*Keith A. Foster*

PERSPECTIVE

FEATURE**84 The rise of micropharma***Christopher J. Barden and Donald F. Weaver*

MONITOR

158 The importance of aryl C–Cl... π interaction in ligand–protein binding*Kap-Sun Yeung***159 DIARY**